Lisa Olson - Aug 2, 2021 Form 4 Insider Report for Magenta Therapeutics, Inc. (DNTH)

Role
Title: Head of Research and Chief Scientific Officer
Signature
/s/ Cindy Driscoll, Attorney-in-Fact for Lisa Olson
Stock symbol
DNTH
Transactions as of
Aug 2, 2021
Transactions value $
$0
Form type
4
Date filed
8/3/2021, 04:39 PM
Previous filing
Jul 22, 2021
Next filing
Sep 16, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNTH Stock Option (Right to Buy) Award $0 +12.5K $0.00 12.5K Aug 2, 2021 Common Stock 12.5K $7.11 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable in 16 equal quarterly installments beginning on August 2, 2021.

Remarks:

Title: Head of Research and Chief Scientific Officer